Published in final edited form as:

J Am Chem Soc. 2006 February 22; 128(7): 2178–2179. doi:10.1021/ja057592b.

Asymmetric Synthesis of 4,5,6- and 3,4,5,6-Substituted Azepanes by a Highly Diastereoselective and Enantioselective Lithiation-Conjugate Addition Sequence

Suk Joong Lee and Peter Beak*

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801

Abstract

Asymmetric syntheses of 4,5,6- and 3,4,5,6-substituted azepanes have been achieved by highly diastereoselective and enantioselective (–)-sparteine mediated asymmetric lithiation-conjugate additions of *N*-Boc-*N*-(*p*-methoxyphenyl)-2,3-substituted allylamines to a β -aryl α,β -unsaturated esters followed by hydrolysis, cyclization and reduction. Access to the enantiomeric adduct is provided by an invertive lithiation-stannylation-lithiation sequence.

Azepane rings are present in a number of biologically interesting molecules and are homologs of the five- and six-membered nitrogen heterocycles which have been extensively developed as core pharmacophores. Methodology for the asymmetric synthesis of polysubstituted azepanes has not been developed. Syntheses of enantioenriched azepane rings have been reported coincident to the preparations of specific compounds of biological interest but general approaches, particularly for substitutions non adjacent to the nitrogen atom, have not been available.^{1,2,3}

We now wish to report lithiation-addition methodology for the asymmetric synthesis of both enantiomers of 4,5,6 and 3,4,5,6 carbon substituted azepanes. The key step in our approach is a highly diastereoselective and enantioselective conjugate addition of a lithiated *N*-Boc-2,3-substituted allylamine to a β -aryl α,β -unsaturated ester which is shown as the first step in the retro-synthetic analysis of Scheme 1.

(–)-Sparteine mediated asymmetric lithiation of *N*-Boc-*N*-(*p*-methoxyphenyl)-2,3-substituted allylamines with *n*-BuLi at -78°C followed by conjugate additions to ethyl trans-*p*-bromocinnamate provides the highly diastereo- and enantioenriched enecarbamates **1–3** in the yields as shown in Table 1. The absolute configuration of **3**, determined by X-ray crystallography, indicates that the stereochemical course of the conjugate addition is inversion of configuration.⁴

Conversion of ester **3** to the amides **6** and **9**,^{6a} followed by acid hydrolysis of the enamide to the aldehyde and subsequent cyclization provided the corresponding *N*-alkyl 2,3,4,5-

tetrahydroazepines **7** and **10** as shown in Scheme 2.⁷ Reductive conversions of **7** and **10** to **8** and **11** were accompanied by debrominations of the aromatic ring.^{6b}

Efficient syntheses of 4,5,6-substituted azepanes are shown in Scheme 3. Enantioenriched **1**, **2** and **3** were converted to the corresponding 4,5,6-substituted *N*-Boc azepanes **16**, **21** and **26** in high yields via aminolysis, hydrolysis, reduction, debenzylation and addition of the Boc group. The stereochemistry at the C-6 positions of **14**, **19** and **24** generated by hydrogenation was identified as *trans* geometry by X-ray crystallography as well as by ¹H NMR analysis.^{7, 8}

Enolization and substitution of the lactam **29** provides a route to 3,4,5,6-substituted azepanes as shown in Scheme 4.⁹ Amino-lysis of **1** with *p*-anisidine to **27** followed by hydrolysis and hydrogenation provided **29**.⁸ Substitutions of **29** by selected electrophiles using LDA as the base provided (*R,S,R,S*)-**30–33** and (*S,S,R,S*)-**34** in good yields with high diastereoselectivities (Table 2). In all cases, the C-3 and C-4 stereochemistry is assigned as *trans* by ¹H NMR analysis.⁸ Dearylation of **31** by CAN^{6c} proceeds smoothly to give (*R,S,R,S*)-**35** in good yield with diastereomeric and enantiomeric purities greater than 98:2.

In order to provide a route to the enantiomeric azepanes, we have taken advantage of the lithiation-stannylation-lithiation sequence which provides the epimeric *N*-Boc substituted allyl-lithium intermediate.⁴ The sequence leading to (*R,S*)-**1** is shown in Scheme 5.¹⁰ The enantiomeric ratio of (*R,S*)-**1** was assessed to be 99:1 by determination of diastereomeric ratio of (*R,S,S*)-**4** after aminolysis of (*R,S*)-**1** with (*S*)-(–)- α -methylbenzylamine.^{7,11} Use of the sequences in Scheme 3 and Scheme 4 with (*R,S*)-**1** would provide the enantiomeric azepanes.

In summary, enantioselective synthesis of both enantiomers 4,5,6- and 3,4,5,6-substituted azepanes can be achieved from the highly diastereoenriched and enantioenriched enecarbamates **1–3** generated by (–)-sparteine mediated asymmetric deprotonative lithiations-conjugate additions of *N*-Boc-*N*-(*p*-methoxyphenyl)-2,3-substituted allylamines. Opening the ring of the lactam intermediates and/or further substitutions at positions adjacent to nitrogen in the intact ring are available for further development.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgements

We are grateful to the National Institutes of Health (GM-18874) and to funds provided by the James R. Eiszner Chair for the support of this work.

References

1. For recent reviews which include azepane ring syntheses, see: (a) Yet L. Chem Rev 2000;100:2963–3007. (b) Kantorowski EJ, Kurth MJ. Tetrahedron 2000;56:4317–4353. (c) Maier ME. Angew Chem Int Ed 2000;39:2073–2077.
2. For recent syntheses of compounds of biological interest containing azepane rings, see: (a) Jacobi PA, Lee KA. J Am Chem Soc 2000;122:4295–4303. (b) Boeckman RK, Clark TJ, Shook BC. Org Lett 2002;4:2109–2112. [PubMed: 12049530] (c) Smith AB III, Cho YS, Pettit GR, Hirschmann R. Tetrahedron 2003;59:6991–7009. (d) Painter GF, Eldridge PJ, Falshaw A. Bioorg Med Chem 2004;12:225–232. [PubMed: 14697787] (e) Li H, Bleriot Y, Mallet JM, Rodriguez-Garcia E, Vogel P, Zhang Y, Sinay P. Tetrahedron: Asymmetry 2005;16:313–319. (f) Wipf P, Spencer SR. J Am Chem Soc 2005;127:225–235. [PubMed: 15631472]
3. For asymmetric azepane syntheses with one or two carbons and, in some cases, an oxygen or nitrogen as substituents, see: (a) Lautens M, Fillion E, Sampat M. J Org Chem 1997;62:7080–7081. [PubMed:

11671802] (b) Masse CE, Morgan AJ, Panek JS. *Org Lett* 2000;2:2571–2573. [PubMed: 10990399] (c) Meyers AI, Downing SV, Weiser MJ. *J Org Chem* 2001;66:1413–1419. [PubMed: 11312974] (d) Cutri S, Bonin M, Micouin L, Husson HP. *J Org Chem* 2003;68:2645–2651. [PubMed: 12662034] (e) Sahasrabudhe K, Gracias V, Furness K, Smith BT, Katz CE, Reddy DS, Aube J. *J Am Chem Soc* 2003;125:7914–7922. [PubMed: 12823012] (f) Alibes R, Blanco P, Casas E, Closa M, March PD, Figueredo M, Font J, Sanfeliu E, Alvarez-Larena A. *J Org Chem* 2005;70:3157–3167. [PubMed: 15822978]

4. (a) Kim DD, Lee SJ, Beak P. *J Org Chem* 2005;70:5376–5386. [PubMed: 15989316] and references cited therein. For more complete reference to related heteroatom allyl lithiums, see also: (b) Whisler MC, Beak P. *J Org Chem* 2003;68:1207–1215. [PubMed: 12585857] (c) Ozlgedik M, Kristensen J, Wibbeling B, Frölich R, Hoppe D. *Eur J Org Chem* 2002:414–427.
5. The diastereomeric ratios of (*S*, *R*, *S*)-4 and (*S*, *R*, *S*)-5 were determined to be 96:4 and 98:2 by ^1H NMR analysis, respectively.

6. (a) Basha A, Lipton M, Weinreb SM. *Tetrahedron Lett* 1977;48:4171–4174. (b) Wanner MJ, Koomen GJ. *Tetrahedron Lett* 1989;30:2301–2304. (c) Kronenthal DR, Han CY, Taylor MK. *J Org Chem* 1982;47:2765–2768.
7. The absolute configurations of 7, 24, 36 and (*R*, *S*, *S*)-4 were established by X-ray crystallography structures. Crystallographic data for structures 7, 24, 36 and (*R*, *S*, *S*)-4 have been deposited with the Cambridge Crystallographic Data Centre as supplementary CCDC numbers 286543, 286544, 286545 and 286546, respectively. These data can be obtained free of charge from the Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
8. Coupling constants between H₅ on C-5 and H₆ on C-6 for 14, 19, 24, 29 and between H₃ on C-3 and H₄ on C-4 for 30–34 are the typical *trans*-coupling constants ($J_{\text{H-H}} = 10.4\text{Hz}$). See supporting information.
9. Attempted enolization-substitution of 24 resulted in substitution at benzylic carbon due to benzylic metalation. See: Meyers AI, Kunnen KB, Still WC. *J Am Chem Soc* 1987;109:4405–4407.
10. The enantiomeric ratio (er = >99:1) of (*R*)-36 was directly determined by CSP-HPLC, after crystallization.
11. The diastereomeric ratio of (*R*, *S*, *S*)-4 was determined to be 99:1 by ^1H NMR analysis.

Scheme 1.

Scheme 2.

Scheme 3.

Scheme 4.

Asymmetric synthesis of 3,4,5,6-substituted azepanes

Scheme 5.
Enantioselective synthesis of enantiomer (*R,S*)-1

Table 1

(-)-Sparteine mediated asymmetric lithiation-substitution sequences

R ¹	R ²	Product	Yield(%)	dr ^a er
CH ₃	CH ₃	(Z,S,R)-1	92	95:5 ^b
Ph	CH ₃	(Z,S,R)-2	86	93:7 ^b
(CH ₂) ₂	(CH ₂) ₂	(Z,S,R)-3	75	96:4 ^b 99:1 ^c

^a Diastereomeric ratios (dr) were determined by ¹H NMR analysis.

^b Enantiomeric ratios (er) were assessed to be >95:5 and >97:3 after aminolysis of **1** and **2** with (S)-(-)-α-methylbenzylamine, respectively.⁵

^c The enantiomeric ratio of **3** was determined by CSP-HPLC analysis.

Table 2

Substitutions of **29**

<p>(Ar=<i>p</i>-Methoxyphenyl-)</p> <p>29</p> <p>30 ~ 34</p>			
Electrophile	Product	Yield(%)	dr
CH ₃ I	(<i>R,S,R,S</i>)- 30	96	98:2
<i>p</i> -BrPhCH ₂ Br	(<i>R,S,R,S</i>)- 31	94	98:2
CH ₂ =CHCH ₂ Br	(<i>R,S,R,S</i>)- 32	73	99:1
(<i>R,S,R,S</i>)- 33	71	99:1
(<i>S,S,R,S</i>)- 34	82	95:5